Form 4: Palatin Technologies Executive VP and CFO/COO Stephen T. Wills Reports Stock and Option Awards
SEC Form 4
Stephen T. Wills, Executive VP and CFO/COO of Palatin Technologies, reports the acquisition of stock and option awards related to the company's 2011 Stock Incentive Plan.
Summary
- Stephen T. Wills, Executive VP and CFO/COO of Palatin Technologies, filed a Form 4 detailing changes in beneficial ownership.
- On July 15, 2024, Wills acquired 69,000 shares of common stock as restricted share units under the 2011 Stock Incentive Plan, vesting at 25% per year starting June 4, 2025.
- On June 4, 2024, Wills acquired several tranches of restricted share units totaling 28,990 shares, which vested based on the achievement of a performance objective related to 85% of the target number of share units for the fiscal year ended June 30, 2024.
- These shares will be issued on or before the 60th day following June 4, 2024.
- On June 4, 2024, Wills also acquired stock options for a total of 149,085 shares with various exercise prices and expiration dates, also under the 2011 Stock Incentive Plan.
- These options vest at a rate of 25% per year, with the initial vesting on June 4, 2025, or vested in part on June 4, 2024, upon certification by the Compensation Committee that a defined performance objective as to 85% of the target number of share units for the fiscal year ended June 30, 2024.
- Following these transactions, Wills directly owns 325,626 shares of common stock and holds options for 326,501 shares.
Sentiment
Score: 6
Explanation: The document is a neutral regulatory filing. The grants are a positive for the executive, but the overall sentiment is neutral as it's a routine disclosure.
Positives
- The grants of restricted share units and stock options align executive compensation with company performance and shareholder value.
- The vesting schedules of the awards encourage long-term commitment from the executive.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted share units are common in the biotechnology industry to incentivize performance and align executive interests with those of shareholders.
- Vesting schedules and performance-based criteria are also standard features of these compensation packages.
Stakeholder Impact
- Shareholders can monitor executive compensation and alignment of interests through this filing.
- Employees may be indirectly impacted by the performance incentives tied to these awards.
Key Dates
| Date | Description |
|---|---|
| June 16, 2020 | Date of performance condition grant for restricted share units and stock options. |
| June 22, 2021 | Date of performance condition grant for restricted share units and stock options. |
| June 22, 2022 | Date of performance condition grant for restricted share units and stock options. |
| June 20, 2023 | Date of performance condition grant for restricted share units and stock options. |
| June 4, 2024 | Date of multiple transactions including grants of restricted share units and stock options, and vesting of performance-based awards. |
| June 30, 2024 | End of fiscal year used for performance objective related to vesting of share units. |
| July 15, 2024 | Date of certification by the CFO regarding shareholder approval of the 2011 Stock Incentive Plan, leading to the grant of additional restricted share units and stock options. |
| July 16, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.